Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Virus diversity and escape from immune responses are the biggest challenges to the development of an effective vaccine against HIV-1. We hypothesized that T-cell vaccines targeting the most conserved regions of the HIV-1 proteome, which are common to most variants and bear fitness costs when mutated, will generate effectors that efficiently recognize and kill virus-infected cells early enough after transmission to potentially impact on HIV-1 replication and will do so more efficiently than whole protein-based T-cell vaccines. Here, we describe the first-ever administration of conserved immunogen vaccines vectored using prime-boost regimens of DNA, simian adenovirus and modified vaccinia virus Ankara to uninfected UK volunteers. The vaccine induced high levels of effector T cells that recognized virus-infected autologous CD4(+) cells and inhibited HIV-1 replication by up to 5.79 log10. The virus inhibition was mediated by both Gag- and Pol- specific effector CD8(+) T cells targeting epitopes that are typically subdominant in natural infection. These results provide proof of concept for using a vaccine to target T cells at conserved epitopes, showing that these T cells can control HIV-1 replication in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034 · cited 1×
“In contrast to the STEP study, the RV144 trial, which tested a combination of ALVAC-vectored Env prime and Env protein boost, gave 31% protection against acquisition, most likely through the generation of non-neutralizing anti-Env antibodies [38, 39].”
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“This is a very important step forward, moving from promising preclinical observations in animals to detailed studies in humans, given that immune responses in experimental animals do not always predict how humans will respond [32, 33, 34].”
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,808 · cited 2×
“In contrast to the STEP study, the RV144 trial, which tested a combination of ALVAC-vectored Env prime and Env protein boost, gave 31% protection against acquisition, most likely through the generation of non-neutralizing anti-Env antibodies [38, 39].”
Self-citationBuchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713 · cited 2×
“…505 trials, which all used HAdV-5 as a vector and showed trends of increased acquisition of HIV-1 in vaccine recipients, there is some concern that all adenoviruses may be precluded from use as prophylactic HIV-1 vaccines [32, 46], although more qualified recommendations might be appropriate [47].”
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load
Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1520 · Cited by 1,032 · cited 3×
“Because protective CD8 + T-cell responses in infected patients are mostly specific for Gag [10, 11, 12], while Pol-specific responses are less common [31], we determined whether vaccine induced Pol-specific T cells were as effective in the VIA as those specific for Gag.”
HIV evolution: CTL escape mutation and reversion after transmission
Leslie, A. J., Pfafferott, K. J., Chetty, P., Draenert, R., Addo, M. M., Feeney, M., Tang, Y., Holmes, E. C., Allen, T., Prado, J. G., et al. (2004) · Nature Medicine · doi:10.1038/nm992 · Cited by 847 · cited 1×
“It is known that escape mutations in many of these conserved regions will reduce the HIV-1 fitness [18, 19, 20, 21].”
BackgroundDiversity Considerations in HIV-1 Vaccine Selection
Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H., Bhattacharya, T., et al. (2002) · Science · doi:10.1126/science.1070441 · Cited by 811 · cited 2×
“Vaccine-induced T cells and antibodies face the same two problems: trying to match the enormous variability of the infecting HIV-1 and its subsequent ability to escape immune control by mutation [7].”
Goonetilleke, N., Liu, M. K. P., Salazar-Gonzalez, J. F., Ferrari, G., Giorgi, E., Ganusov, V. V., Keele, B. F., Learn, G. H., Turnbull, E. L., Salazar, M. G., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090365 · Cited by 641 · cited 1×
“Given the HIVconsv epitope subdominance in natural infection, this broadly concurs with a detailed mapping of CD8 + T-cell responses during acute HIV-1 infection, which identified about 30% of previously undescribed epitopes, some of which were in variable regions and escaped early [44].”
Self-citationSáez-Cirión, A., Lacabaratz, C., Lambotte, O., Versmisse, P., Urrutia, A., Boufassa, F., Barré-Sinoussi, F., Delfraissy, J.-F., Sinet, M., Pancino, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611244104 · Cited by 616 · cited 1×
“However, inhibition of HIV-1 replication in activated CD4 + T cells by autologous CD8 + T cells in vitro does correlate well with virus control in vivo [3, 4, 5, 6].”
Kelleher, A. D., Long, C., Holmes, E. C., Allen, R. L., Wilson, J., Conlon, C., Workman, C., Shaunak, S., Olson, K., Goulder, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.3.375 · Cited by 448 · cited 1×
“It is known that escape mutations in many of these conserved regions will reduce the HIV-1 fitness [18, 19, 20, 21].”
Self-citationMartinez-Picado, J., Prado, J. G., Fry, E. E., Pfafferott, K., Leslie, A., Chetty, S., Thobakgale, C., Honeyborne, I., Crawford, H., Matthews, P., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.7.3617-3623.2006 · Cited by 446 · cited 1×
“We reasoned that a vaccine that targets multiple HIV-1 epitopes would provide the greatest barrier to immune escape, especially if these epitopes were derived from functionally conserved regions of the virus [12, 27, 28].”
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
Fischer, W., Perkins, S., Theiler, J., Bhattacharya, T., Yusim, K., Funkhouser, R., Kuiken, C., Haynes, B., Letvin, N. L., Walker, B. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1461 · Cited by 446 · cited 1×
“…HIV-1 vaccine by assembling cocktails of immunogens derived from multiple HIV-1 isolates [8] or computing the most representative aa sequences [7, 9] Another rational approach is to design vaccine immunogens based on the most conserved proteins such as Gag [10, 11, 12], or better yet subprotein…”
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Rolland, M., Edlefsen, P. T., Larsen, B. B., Tovanabutra, S., Sanders-Buell, E., Hertz, T., deCamp, A. C., Carrico, C., Menis, S., Magaret, C. A., et al. (2012) · Nature · doi:10.1038/nature11519 · Cited by 417 · cited 1×
“…T-cell responses, should be a good candidate for progressing to a phase IIb efficacy trial, testing either on its own or better in a combination with vaccines that can elicit broadly neutralizing antibodies or antibodies to the V1/V2 regions of the gp120 Env, as in the RV144 trial [38, 48].”
Confronting Complexity: Real-World Immunodominance in Antiviral CD8+ T Cell Responses
Yewdell, J. W. (2006) · Immunity · doi:10.1016/j.immuni.2006.09.005 · Cited by 364 · cited 2×
“The challenge is that immune responses to these regions are typically subdominant and have to compete for recognition with rapidly changing (and therefore less protective), immunodominant epitopes [22].”
Schneidewind, A., Brockman, M. A., Yang, R., Adam, R. I., Li, B., Le Gall, S., Rinaldo, C. R., Craggs, S. L., Allgaier, R. L., Power, K. A., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01543-07 · Cited by 317 · cited 1×
“We reasoned that a vaccine that targets multiple HIV-1 epitopes would provide the greatest barrier to immune escape, especially if these epitopes were derived from functionally conserved regions of the virus [12, 27, 28].”
Self-citationDesign and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
Létourneau, S., Im, E.-J., Mashishi, T., Brereton, C., Bridgeman, A., Yang, H., Dorrell, L., Dong, T., Korber, B., McMichael, A. J., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000984 · Cited by 281 · cited 5×
“HIVconsv (M) [16, 23].”
InfluentialSelf-citationFerguson, A. L., Mann, J. K., Omarjee, S., Ndung’u, T., Walker, B. D., & Chakraborty, A. K. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.022 · Cited by 233 · cited 1×
“It is known that escape mutations in many of these conserved regions will reduce the HIV-1 fitness [18, 19, 20, 21].”
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
Rolland, M., Tovanabutra, S., deCamp, A. C., Frahm, N., Gilbert, P. B., Sanders-Buell, E., Heath, L., Magaret, C. A., Bose, M., Bradfield, A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2316 · Cited by 225 · cited 1×
“…study where only 77% subjects responded, of whom 62% recognized only 2 – 3 epitopes, and the T-cell responses were often directed against more variable regions of the clade B virus resulting in a sieve effect that selected escape mutants in those subjects who were subsequently HIV-1 infected [37].”
Self-citationInduction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.
Carbone, F. R., & Bevan, M. J. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.3.603 · Cited by 219 · cited 1×
“There is a danger that T-cell responses elicited by artificial peptide based immunogens might be specific for epitopes that are not naturally presented by HIV-1 [29, 30].”
Duerr, A., Huang, Y., Buchbinder, S., Coombs, R. W., Sanchez, J., del Rio, C., Casapia, M., Santiago, S., Gilbert, P., Corey, L., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis342 · Cited by 210 · cited 1×
“…505 trials, which all used HAdV-5 as a vector and showed trends of increased acquisition of HIV-1 in vaccine recipients, there is some concern that all adenoviruses may be precluded from use as prophylactic HIV-1 vaccines [32, 46], although more qualified recommendations might be appropriate [47].”
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape
Liu, M. K. P., Hawkins, N., Ritchie, A. J., Ganusov, V. V., Whale, V., Brackenridge, S., Li, H., Pavlicek, J. W., Cai, F., Rose-Abrahams, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65330 · Cited by 191 · cited 3×
“This is strongly supported by recent analysis of T-cell responses and escape in acute HIV-1 infection [31].”
Self-citationHIV-1 Group M Conserved Elements Vaccine
Rolland, M., Nickle, D. C., & Mullins, J. I. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030157 · Cited by 190 · cited 1×
“…design vaccine immunogens based on the most conserved proteins such as Gag [10, 11, 12], or better yet subprotein regions of the proteome, which are shared by the majority of HIV-1 variants and thus in principle provide a universal vaccine with potential for global deployment [13, 14, 15, 16, 17].”
Walker, B., & McMichael, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007054 · Cited by 189 · cited 1×
“Despite strong evidence that HIV-1-specific CD8+ T cells contribute to the control of HIV-1 replication during both acute and chronic phases of infection, it has been difficult to identify a single phenotypic correlate of protection in humans [2].”
Self-citationInduction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.
Carbone, F. R., Moore, M. W., Sheil, J. M., & Bevan, M. J. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.6.1767 · Cited by 186 · cited 1×
“There is a danger that T-cell responses elicited by artificial peptide based immunogens might be specific for epitopes that are not naturally presented by HIV-1 [29, 30].”
Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads
Rolland, M., Heckerman, D. E., Deng, W., Rousseau, C. M., Coovadia, H. M., Bishop, K. S., Goulder, P., Walker, B. D., Brander, C., & Mullins, J. I. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001424 · Cited by 155 · cited 4×
“…aa sequences [7, 9] Another rational approach is to design vaccine immunogens based on the most conserved proteins such as Gag [10, 11, 12], or better yet subprotein regions of the proteome, which are shared by the majority of HIV-1 variants and thus in principle provide a universal…”
InfluentialChurchyard, G., Morgan, C. A., Adams, E. M., Hural, J., Graham, B. S., Moodie, Z., Grove, D., Gray, G., Bekker, L., McElrath, M. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021225 · Cited by 149 · cited 2×
“…have been made to tackle these major challenges for an HIV-1 vaccine by assembling cocktails of immunogens derived from multiple HIV-1 isolates [8] or computing the most representative aa sequences [7, 9] Another rational approach is to design vaccine immunogens based on the most conserved…”
Frahm, N., deCamp, A. C., Friedrich, D. P., Carter, D. K., Defawe, O., Kublin, J. G., Casimiro, D. R., Duerr, A. C., Robertson, M. N., Buchbinder, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60202 · Cited by 146 · cited 1×
“However, it is unlikely that these T-cell responses will interfere with the induction of relevant anti-HIV-1 responses any more that the anti-vector T cells [45] and they will certainly not compete for recognition of HIV-1-infected cells.”
Self-citationHoneyborne, I., Prendergast, A. J., Pereyra, F., Leslie, A. J., Crawford, H., Payne, R., Reddy, S., Bishop, K. S., Moodley, E. S., Nair, K., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02689-06 · Cited by 146 · cited 3×
“…most representative aa sequences [7, 9] Another rational approach is to design vaccine immunogens based on the most conserved proteins such as Gag [10, 11, 12], or better yet subprotein regions of the proteome, which are shared by the majority of HIV-1 variants and thus in principle provide a…”
Hanke, T., McMichael, A. J., & Dorrell, L. (2006) · Journal of General Virology · doi:10.1099/vir.0.82493-0 · Cited by 140
Self-citationFreel, S. A., Lamoreaux, L., Chattopadhyay, P. K., Saunders, K. O., Zarkowsky, D., Overman, R. G., Ochsenbauer, C., Edmonds, T. G., Kappes, J. C., Cunningham, C. K., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00138-10 · Cited by 119 · cited 2×
“This concurs with comparison of DNA/HAdV-5 vaccinees with chronically infected patients [35].”
Barouch, D. H., Liu, J., Peter, L. E., Abbink, P., Iampietro, M. J., Cheung, A., Alter, G., Chung, A. W., Dugast, A., Frahm, N., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis671 · Cited by 118 · cited 1×
“Other vaccine designs tested in phase I trials have also given weaker T-cell responses, often in less than 100% of vaccine recipients and have not focused on conserved epitopes [8, 40, 41, 42, 43].”
Self-citationMcCormack, S., Stöhr, W., Barber, T., Bart, P., Harari, A., Moog, C., Ciuffreda, D., Cellerai, C., Cowen, M., Gamboni, R., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.02.072 · Cited by 111 · cited 1×
“Other vaccine designs tested in phase I trials have also given weaker T-cell responses, often in less than 100% of vaccine recipients and have not focused on conserved epitopes [8, 40, 41, 42, 43].”
Lessons learned from HIV-1 vaccine trials: new priorities and directions
McMichael, A. J., & Haynes, B. F. (2012) · Nature Immunology · doi:10.1038/ni.2264 · Cited by 103 · cited 1×
“Ideally, such a vaccine should induce broadly neutralizing antibodies and protective T cells at the same time [1], although either one of these arms alone, if effective, could have an impact on the epidemic.”
Self-citationCurrier, J. R., Ngauy, V., de Souza, M. S., Ratto‐Kim, S., Cox, J. H., Polonis, V. R., Earl, P. L., Moss, B., Peel, S. A., Slike, B. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013983 · Cited by 80 · cited 1×
“Other vaccine designs tested in phase I trials have also given weaker T-cell responses, often in less than 100% of vaccine recipients and have not focused on conserved epitopes [8, 40, 41, 42, 43].”
Self-citationYang, H., Wu, H., Hancock, G., Clutton, G., Sande, N., Xu, X., Yan, H., Huang, X., Angus, B., Kuldanek, K., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis379 · Cited by 79 · cited 2×
“However, inhibition of HIV-1 replication in activated CD4 + T cells by autologous CD8 + T cells in vitro does correlate well with virus control in vivo [3, 4, 5, 6].”
Self-citationSpentzou, A., Bergin, P. J., Gill, D. K., Cheeseman, H. M., Ashraf, A., Kaltsidis, H., Cashin‐Cox, M., Anjarwalla, I., Steel, A., Higgs, C. J., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/650492 · Cited by 76 · cited 2×
“However, inhibition of HIV-1 replication in activated CD4 + T cells by autologous CD8 + T cells in vitro does correlate well with virus control in vivo [3, 4, 5, 6].”
Self-citationRosario, M., Bridgeman, A., Quakkelaar, E. D., Quigley, M. F., Hill, B. J., Knudsen, M. L., Ammendola, V., Ljungberg, K., Borthwick, N., Im, E., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040344 · Cited by 75 · cited 3×
“HIVconsv (M) [16, 23].”
Self-citationFreel, S. A., Picking, R. A., Ferrari, G., Ding, H., Ochsenbauer, C., Kappes, J. C., Kirchherr, J., Soderberg, K. A., Weinhold, K. J., Cunningham, C. K., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00437-12 · Cited by 62 · cited 1×
“Given the good prospective correlations between strong virus suppression, delayed loss of CD4 + T cells and lower viral load set-point, VIA could be a highly clinically relevant assay for the assessment of the likely efficacy of CD8 + T cell-inducing vaccines [6, 35, 36].”
Self-citationCombined approaches for HIV cure
Margolis, D., & Hazuda, D. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32835ef089 · Cited by 60 · cited 1×
“Also this platform, if immunogenic in HIV-1-positive individuals, would be very appropriate for studies aimed at eliminating HIV-1 reservoirs, in conjunction with antiretroviral treatment and reactivation of the latent virus [49].”
Knudsen, M. L., Mbewe‐Mvula, A., Rosario, M., Johansson, D. X., Kakoulidou, M., Bridgeman, A., Reyes‐Sandoval, A., Nicosia, A., Ljungberg, K., Hanke, T., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06535-11 · Cited by 54 · cited 1×
“Prior to clinical studies, we demonstrated safety [24] and high immunogenicity of the HIVconsv vaccines in mice and macaques [16, 23, 25, 26].”
Self-citationRosario, M., Borthwick, N., Stewart-Jones, G. B. E., Mbewe‐Mvula, A., Bridgeman, A., Colloca, S., Montefiori, D. C., McMichael, A. J., Nicosia, A., Quakkelaar, E. D., et al. (2011) · AIDS · doi:10.1097/qad.0b013e32834ed9b2 · Cited by 38 · cited 1×
“Prior to clinical studies, we demonstrated safety [24] and high immunogenicity of the HIVconsv vaccines in mice and macaques [16, 23, 25, 26].”
Self-citationHIV-1–specific CTLs effectively suppress replication of HIV-1 in HIV-1–infected macrophages
Fujiwara, M., & Takiguchi, M. (2007) · Blood · doi:10.1182/blood-2006-07-037481 · Cited by 37 · cited 1×
“However, inhibition of HIV-1 replication in activated CD4+ T cells by autologous CD8+ T cells in vitro does correlate well with virus control in vivo [3, 4, 5, 6].”
HIV‐1: From escapism to conservatism
Hanke, T., & McMichael, A. J. (2011) · European Journal of Immunology · doi:10.1002/eji.201190072 · Cited by 14 · cited 1×
“…design vaccine immunogens based on the most conserved proteins such as Gag [10, 11, 12], or better yet subprotein regions of the proteome, which are shared by the majority of HIV-1 variants and thus in principle provide a universal vaccine with potential for global deployment [13, 14, 15, 16, 17].”
Self-citationWilson, N. A., & Watkins, D. I. (2009) · The Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702009000400013 · Cited by 14 · cited 1×
“This is a very important step forward, moving from promising preclinical observations in animals to detailed studies in humans, given that immune responses in experimental animals do not always predict how humans will respond [32, 33, 34].”
Ondondo, B., Brennan, C., Nicosia, A., Crome, S. J., & Hanke, T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.068 · Cited by 12 · cited 1×
“Prior to clinical studies, we demonstrated safety [24] and high immunogenicity of the HIVconsv vaccines in mice and macaques [16, 23, 25, 26].”
Self-citationRichie, T. L., & Villasante, E. F. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis737 · Cited by 6 · cited 1×
“…505 trials, which all used HAdV-5 as a vector and showed trends of increased acquisition of HIV-1 in vaccine recipients, there is some concern that all adenoviruses may be precluded from use as prophylactic HIV-1 vaccines [32, 46], although more qualified recommendations might be appropriate [47].”
Cited by
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348
Self-citationMoyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
“epitopes irrelevant for HIV-1 generated by two juxtaposed regions.(20) (B) Vaccines used in this work.”
MethodSelf-citation5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
Cappuccini, F., Pollock, E., Stribbling, S., Hill, A. V. S., & Redchenko, I. (2017) · Oncotarget · doi:10.18632/oncotarget.17666 · Cited by 31
Self-citation
Metadata
- Authors
- Borthwick, N., Ahmed, T., Ondondo, B., Hayes, P., Rose, A., Ebrahimsa, U., Hayton, E.-J., Black, A., Bridgeman, A., Rosario, M., Hill, A. V., Berrie, E., Moyle, S., Frahm, N., Cox, J., Colloca, S., Nicosia, A., Gilmour, J., McMichael, A. J., Dorrell, L., & Hanke, T.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 22
- Issue
- 2
- Pages
- 464-475
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1991737813
- Cited by
- 199
- References
- 46
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.